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Abstract
Background: Peripheral neuropathy (PN) is common in patients with diseases that are 
in turn associated with deficiency of the B- vitamins, and vitamin treatment has shown 
mixed results.
Methods: This systematic review and meta- analysis studied the association between PN/
pain and B- vitamin biomarkers and investigated whether vitamin treatment can amelio-
rate the symptoms. PubMed and Web of Science were searched according to the study 
protocol.
Results: A total of 46 observational and seven interventional studies were identified and 
included in the data synthesis. The presence of PN was associated with lowered B12 
levels (pooled estimate [95% CIs] = 1.51 [1.23– 1.84], n = 34, Cochran Q Test I2 = 43.3%, 
p = 0.003) and elevated methylmalonic acid (2.53 [1.39– 4.60], n = 9, I2 = 63.8%, p = 0.005) 
and homocysteine (3.48 [2.01– 6.04], n = 15, I2 = 70.6%, p < 0.001). B12 treatment (vs. 
the comparators) showed a non- significant association with symptom improvement (1.36 
(0.66– 2.79), n = 4, I2 = 28.9%). Treatment with B1 was associated with a significant im-
provement in symptoms (5.34 [1.87– 15.19], n = 3, I2 = 64.6%, p = 0.059). Analysis of seven 
trials combined showed a non- significant higher odds ratio for improvement under treat-
ment with the B- vitamins (2.58 [0.98– 6.79], I2 = 80.0%, p < 0.001).
Conclusions: PN is associated with lowered plasma vitamin B12 and elevated methyl-
malonic acid and homocysteine. Overall, interventional studies have suggested that B- 
vitamins could improve symptoms of PN. Available trials have limitations and generally 
did not investigate vitamin status prior to treatment. Well- designed studies, especially 
in non- diabetes PN, are needed. This meta- analysis is registered at PROSPERO (ID: 
CRD42020144917).
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INTRODUC TION
Peripheral neuropathy (PN) is generalized nerve damage of the pe-
ripheral nerve system. The age- standardized prevalence of PN in the 
general population is 9.4%.1 The etiology of PN is not well character-
ized. Approximately 31% of patients with PN have diabetes and 46% 
of neuropathies are idiopathic.1
Vitamin B12 deficiency causes spinal cord lesion or subacute 
combined degeneration where a demyelination process leads to 
decay of the myelin sheath in the dorsal and lateral columns.2,3 In 
older patients with Parkinson’s disease, neuropathy could be due 
to levodopa (L- dopa) treatment that causes vitamin B12 deficiency. 
Also, toxins such as alcohol and viral infections are associated with 
vitamin B12 deficiency and neuropathy.2,3 Thus, vitamin B12 defi-
ciency could be causally related to PN. The mechanisms could in-
volve hypomethylation, phospholipid metabolism, and neurotoxic 
effects of homocysteine.4
Diagnosis of PN and differential diagnosis of similar disorders 
(i.e., myelopathy) 5 is challenging. Disease history and symptoms 
such as numbness, parenthesis, pain, and/or dysesthesias provide 
important clues to the diagnosis. The diagnosis relies on medical his-
tory, symptoms, clinical examination (i.e., ankle reflexes), and labo-
ratory tests.6 Additionally, nerve conduction studies (peroneal and 
posterior tibial nerves) help determine the type of nerve damage (ax-
onal or demyelinating), distribution (symmetric or asymmetric, distal, 
or proximal), and severity.
Therapeutic doses of the B- vitamins (B1, B6, and/or B12) are 
commonly used in patients with PN but there are no evidence- based 
guidelines as to whether vitamin deficiency should be suspected or 
treated in such patients.7 The present systematic review and meta- 
analysis investigated the association between low statuses of the 
B- vitamins and the presence of PN/pain and the effect of vitamin 
treatment on PN/pain symptoms. We studied the odds of patients 
with PN/pain having lowered vitamin biomarkers compared to those 
without PN/pain, and whether neuropathy symptoms are more likely 
to improve after treatment with vitamins B1, B6, and/or B12 than 
after a control treatment.
METHODS
The study is registered at the International Prospective Register of 
Systematic Reviews (PROSPERO) (ID: CRD42020144917). The pro-
tocol was prepared before starting the search.
Search and screening strategies
The search, screening, and data abstraction were independently 
conducted by JS and RO. The search was conducted in PubMed and 
Web of Science on 18 September 2018 using the terms shown in 
Table S1. A manual search of the grey literature and the references 
of relevant reviews was performed. We screened the titles and 
abstracts followed by the full texts of potentially relevant articles. 
The corresponding authors of relevant articles published between 
January 2010 and September 2018 were asked to provide additional 
data.
We included human studies of adult men and women. Neuropathy 
could be idiopathic or associated with viral infections, cancer, renal 
insufficiency, carpal tunnel syndrome, chemotherapy, alcoholism, 
diabetes, or Parkinson’s disease. The design of observational stud-
ies could be cohort, case- control, or cross- sectional. Studies should 
report plasma/serum concentrations of vitamins B1, B6, and/or B12 
(vitamin B12 [or holotranscobalamin], B1, B6); functional markers 
such as total homocysteine (tHcy) or methylmalonic acid (MMA); or 
functional enzymatic tests. We applied no restriction to the clinical 
tests used to diagnose PN and pain.
The design of interventional studies could be randomized- or 
quasi- randomized- controlled, open- labelled, or single or double- 
blind. The comparators could be placebo, no treatment, or non- drug 
comparators (i.e., Chinese herbs). All dosages, routes of adminis-
tration, combinations, durations, and forms of the vitamins (i.e., 
thiamine- HCl, benfothiamine, cyanocobalamin, and methylcobala-
min) were eligible. Studies testing vitamins plus a drug versus the 
drug without the vitamins could be included. The outcome of the 
intervention studies was improvement of PN/pain syndromes (vs. 
no improvement/worsened). No restriction was applied to the med-
ical tests used to evaluate PN or pain. In studies applying multiple 
tests to diagnose PN, alternative tests were used in the sensitivity 
analyses.
We excluded multiple publications, non- English language arti-
cles, reviews, case series, case reports, studies not measuring bio-
markers, studies with <20 participants, and when all patients were 
deficient or all received vitamins. We excluded studies in children, 
pregnant women, patients with liver disorders, inherited diseases 
associated with neuropathy, optic neuropathy, autonomic neurop-
athies, reports on vitamin B6 overdose- induced neuropathy, pain 
caused by an acute trauma, accidents, or operations, studies on 
cerebrospinal fluid biomarkers, and trials testing vitamins against 
drugs. Intervention studies in patients with herpes infection and 
carpal tunnel syndrome were excluded.
Data extraction
We documented PMID, first author, publication year, design, num-
ber (n) of participants, n male/n female, age, recruitment years, coun-
try, setting, inclusion and exclusion criteria, suspected main disease 
associated with PN, medications, comorbidities, PN/pain diagnostic 
tests, vitamin biomarkers, analytical methods used to measure the 
markers, study- specific definition of a low vitamin status, and n of 
deficient/sufficient patients with PN/pain and those without PN/
pain. For treatment studies, we documented n of responders (im-
proved) and non- responders (not improve/worsened) in each treat-
ment arm. The information was captured in 2*2 contingency and 
Excel tables.
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Data tabulation and statistical analyses
The effect size to be analyzed was the odds ratio (OR) and 95% 
confidence intervals (95% CIs) that were calculated for each vi-
tamin marker and clinical test result. A Mantel−Haenszel- type es-
timator in a random effect model was used where each study is 
weighted by the inverse of its variance. Pooled estimates and 95% 
CIs were calculated from the individual OR. The results were meta- 
analyzed when the number of studies was ≥3 and Forest plot was 
used to plot the data. Cochran Q Test and I2 were used to study 
the heterogeneity between the studies. Sources of heterogene-
ity were investigated in subgroup analyses. Publication bias was 
investigated by using Egger's regression that tests the hypothesis 
that the regression intercept is zero. Duval and Tweedie's “trim 
and fill” method was applied to correct the point estimates for 
publication bias. Funnel plot of the standard error (SE) by log- OR 
are presented for the main analyses. Values of p <0.05 were con-
sidered statistically significant. The data analyses were conducted 
using the Comprehensive Meta- Analysis software programme 
(version 3.0).
Subgroup, sensitivity, and post hoc analyses
The association between PN and lowered vitamin B12 was studied 
according to the continent of the study origin (i.e., due to different 
medical practices and prevalence of deficiencies); the underlying 
diseases; publication years; and cut- off values used to define low 
vitamin B12. Studies in patients with diabetes were additionally 
analyzed according to metformin use. Moreover, we used a global 
definition of vitamin B12 deficiency that prioritizes the markers as 
follows: vitamin B12 as the first line marker, followed by MMA, and 
tHcy. The data analyses were repeated after excluding the stud-
ies one- by- one and evaluating the consistency of the estimates. 
We conducted post hoc analysis of the association between low 
plasma folate and PN from the studies that we identified in the 
present search.
For the primary analyses of intervention studies that included 
multiple clinical tests we used the most objective test (i.e., clinical 
examination by a physician) to define improvement. The sensitiv-
ity analyses included results of less certain tests (i.e., self- reported 
symptoms). In studies with several follow- up time points, the main 
analyses included the later time point (i.e., Parkinson’s disease after 
receiving L- dopa), while the results in drug- näive subjects were ana-
lyzed in the sensitivity analyses.
We used the study quality and bias assessment tools accord-
ing to the Newcastle−Ottawa Scale for case−control studies8 and 
the revised form adapted for cross- sectional studies.9 The overall 
quality was interpreted from the total scores.10 The revised tool 
for assessing risk of bias in randomized trials (RoB 2) was used.11 




The initial search identified 5174 articles, of which 1329 titles and 
abstracts were screened and 1078 were excluded (Figure 1). The 
remaining 251 articles plus one article that was identified from the 
reference list of a meta- analysis7 passed to the full- text screening 
that led us to exclude a further 198 articles. We contacted 36 au-
thors, of whom 13 provided additional data, while 16 potentially 
relevant articles were not included due to failed or implausible re-
plies. The data were approximated from the figures or tables in nine 
studies.12– 20 The final analysis included 46 observational studies on 
B- vitamin markers in patients with and without PN13– 57 (Tables S2– 
S4) and seven intervention studies with B- vitamins in patients with 
PN 58– 64 (Table 1 and Table S5). A study on non- neuropathic pain 
was excluded 65
Observational studies
The prevalence of lowered plasma vitamin B12 was reported in 32 
independent studies among 2948 individuals with neuropathy and 
9423 individuals without neuropathy (Tables S2−S4). One study 
was excluded from the data analyses because none of the partici-
pants had low vitamin B12.53 Two studies had multiple groups of pa-
tients.24,34 We found that neuropathy was associated with lowered 
vitamin B12 levels [pooled estimate (95% CIs) = 1.51 (1.23– 1.84)] 
(Figure 2). The studies showed a moderate heterogeneity (Cochran 
Q Test I2 = 43.3%, p = 0.003) and no publication bias (p = 0.065) 
(Figure S1A).
The association was not significant in a subgroup of Asian studies 
(1.43 [0.87– 2.36], n = 10, I2 = 63.5%, p = 0.003).18,20,25,29,34,36,37,45,51 
The European14,17,22,26,28,30,32,38,42,46,47,57 and the North American 
studies15,19,24,35,40,41,43,44,52,56 showed significant associations be-
tween lowered vitamin B12 and PN (1.66 [1.20– 2.31], n = 12, 
I2 = 13.4%, p = 0.314) and (1.55 [1.14– 2.10], n = 11, I2 = 44.8%, 
p = 0.053), respectively (Figure S2).
The presence of neuropathy was associated with lowered vita-
min B12 concentrations among patients with diabetes (1.27 [0.87– 
1.85], n = 11, I2 = 49.7%, p = 0.030) 22– 24,26,32,34,37,45,51; HIV infection 
(9.20 [1.85– 45.82], n = 3, I2 = 0%, p = 0.908) 19,35,40; Parkinson’s dis-
ease (2.74 [1.74– 4.31], n = 7, I2 = 0%, p = 0.894) 14,17,18,30,42,46,47; and 
in idiopathic- 15,20,25,28,29,36,43,44,52,56,57 and alcohol- related neuropa-
thies15,57 combined (1.37 [1.06– 1.78], n = 13, I2 = 43.6%, p = 0.047) 
(Figure S3). Neuropathy was not significantly associated with low-
ered vitamin B12 in five studies among patients receiving metformin 
(1.50 [0.77– 2.94], I2 = 69.1%, p = 0.011) and in six studies among 
patients not exclusively treated with metformin (1.10 [0.72– 1.68], 
I2 = 16.3%, p = 0.309) (Figure S4).
The association between PN and lowered B12 was significant 
in 22 studies published between 2011 and 2018 (1.54 [1.22– 1.94], 
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I2 = 48.5%, p = 0.006), but not in studies published before 
2000 (n = 5) or those published between 2000 and 2010 (n = 7) 
(Figure S5).
Neuropathy was associated with lowered vitamin B12 defined 
using cut- offs ≥205 ng/L (1.71 [1.20– 2.43], n = 14, I2 = 56.3%, 
p = 0.005) or below 205 ng/L (1.38 [1.04– 1.83], n = 18, I2 = 37.3%, 
p = 0.056) (Figure S6, Table S6).
Nine studies reported concentrations of MMA in relation to the 
presence of neuropathy in 827 individuals with neuropathy and 
1492 without neuropathy.18,21,30,36,38,49,50,52,53 An additional study 
reported a combination of lowered vitamin B12 or elevated MMA.44 
The presence of neuropathy was associated with elevated MMA 
(2.53 [1.39– 4.60], I2 = 63.8%, p = 0.005) (Figure 3). The studies 
showed a significant publication bias (p = 0.033). The pooled esti-
mate after applying Duval and Tweedie's “trim and fill” method was 
1.50 (0.81– 2.78) (Figure S1B). Excluding studies one- by- one did not 
change the results (data not shown).
Neuropathy was associated with elevated plasma tHcy in 
15 studies including 1047 patients with neuropathy and 4763 
without neuropathy (3.48 [2.01– 6.04], I2 = 70.6%, p < 0.001). 
12,14,17,22,27,30,33,38,39,42,44,47,48,52,53 No publication bias was ob-
served (p = 0.276) (Figure 4 and Figure S1C) and no significant 
change of the estimate after one- by- one exclusion of the studies 
(data not shown).
Elevated tHcy was associated with neuropathy in studies among 
patients with Parkinson’s diseases (n = 6) and idiopathic neuropathy 
(n = 4), while the association was not statistically significant in pa-
tients with diabetes (n = 5) (Figure S7).
The sensitivity analysis showed that the association between 
neuropathy and lowered vitamin B12 remained significant after 
replacing one study reporting an alternative definition of lowered 
B12 status and six studies using alternative diagnosis of neuropa-
thy (1.42 [1.14– 1.78], n = 34, I2 = 50.8%, p < 0.001) (Figure S8). This 
association showed publication bias (p = 0.006, Eggers regression 
F I G U R E  1  PRISMA study flow diagram. [Colour figure can be viewed at wileyonlinelibrary.com]
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test). The estimate was 1.06 (0.94– 1.19) after correcting for publi-
cation bias. Also, the association between PN and elevated plasma 
tHcy (2.93 [1.77– 4.84], n = 15, I2 = 77.9%, p < 0.001) or elevated 
MMA (2.20 [1.29– 3.72], n = 9, I2 = 67.8%, p = 0.002) remained 
significant when alternative definition of PN was used in the study 
of Hin et al.38
Neuropathy was associated with low vitamin B12 status de-
fined using a global approach (i.e., B12 > MMA > tHcy) [(1.56 
[1.31– 1.86], n = 43, I2 = 40.6%, p = 0.004) (Figure S9). A signifi-
cant publication bias was detected (p = 0.023), but the adjusted 
estimate remained significant (1.37 [1.24– 1.52]). Neuropathy was 
not significantly associated with lowered vitamin B1 or vitamin B6 
(Figure S10).
Most observational studies were of good or fair quality (Table S7).
Intervention studies
Seven studies used at least one vitamin (B1, B6, or B12) to treat neurop-
athy58– 64 (Table 1). The OR of improvement in patients treated with B12 
(vs. controls) was 1.36 (0.66– 2.79), n = 4, I2 = 28.9% (Figure S11A).58– 60,64 
Similar results were seen when alternative tests were used to define 
improvement (1.23 [0.64– 2.39], I2 = 28.6%, p = 0.241).
The association between symptom improvement after B12 
alone or a combination of B12, B1, and B6 (n = 7) was not sig-
nificant (2.58 [0.98– 6.79], I2 = 80.0%, p < 0.001) (Figure S11B). 
Alternative definitions of improvement yielded similar estimates 
(2.52 [0.98– 6.50], I2 = 80.8%, p < 0.001). The estimates were sig-
nificant when the study of Li et al. 58 or that of McCann et al. 63 
was excluded.
Treatment with vitamin B1 was associated with symptom im-
provement (5.34 [1.87– 15.19], n = 3, I2 = 64.6%, p = 0.059).60– 62 
The sensitivity analysis showed similar results (4.60 [1.24– 17.12]). 
Vitamin B6 was not associated with improvement (2.61 (0.42– 16.36), 
n = 3, I2 = 86.3%, p = 0.001).
There were similar or no side effects in three vitamin trials, while 
four trials did not report safety results61– 64 (Table S8).
Most intervention studies exhibited some concerns in the design 
(Table S9). Violations were often due to underreporting, rather than 
to a clear bias in the study designs.
F I G U R E  2  Forest plot of the association between the presence of peripheral neuropathy (PN) and low plasma concentrations of vitamin 
B12 in observational studies.
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DISCUSSION
We have shown that patients with PN had higher probabilities of 
lowered vitamin B12 (OR = 1.51 [1.23– 1.84]) and elevated MMA 
(2.53 [1.39– 4.60]) and tHcy concentrations (3.48 [2.01– 6.04]) com-
pared to patients without PN. The associations between lowered vi-
tamin B12 and PN were rather consistent in subgroups of countries, 
comorbidities, publication years, and according to cut- off values 
F I G U R E  3  Forest plot of the association between the presence of peripheral neuropathy (PN) and elevated plasma methylmalonic acid 
(MMA) in observational studies.
F I G U R E  4  Forest plot of the association between the presence of peripheral neuropathy (PN) and elevated plasma total homocysteine 
(tHcy) in observational studies.
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of vitamin B12 concentrations. Studies conducted in patients with 
type 2 diabetes explained some of the observed heterogeneity. 
Furthermore, we found a non- significant higher OR of patients with 
PN to show improvement after vitamin B12 treatment compared to 
the comparators. Treatment with vitamin B1 was associated with 
improvement of PN symptoms compared to the control treatments.
Interpretation and translation into practice
Hyperhomocysteinaemia and vitamin B12 deficiency are often de-
tected in patients affected with diseases associated with neuropa-
thy such as diabetes,66 alcoholism,67 Parkinson’s disease (treated 
with L- dopa),68 or HIV infection.69 Vitamin B12 deficiency could be 
a modifiable risk factor for neuropathy in those patients. A previous 
systematic review on the effect of B- vitamins among patients with 
alcohol- and diabetes- neuropathy was inconclusive.7 Our results 
strongly suggest that screening for and treating vitamin B12 defi-
ciency should be recommended for patients at risk for neuropathy 
and those with neuropathy. We have shown that the OR of elevated 
tHcy or MMA in patients with PN was higher than that of lowered 
vitamin B12. This observation supports using tHcy as a screening 
marker, since MMA measurement is expensive and requires highly 
equipped laboratories. Although the vitamin B12 test is widely used, 
lowered vitamin B12 concentrations show low sensitivity in detect-
ing deficiency. Moreover, higher MMA and tHcy in elderly people 
and those with renal insufficiency, especially in patients with dia-
betes, may have increased the heterogeneity of the analysis and re-
duced the chance of detecting significant associations in subgroup 
analysis.
There is a need for consensus regarding the selection of mark-
ers to be used in detecting vitamin B12 deficiency in patients with 
PN. The German Society of Neurology recommended screening for 
vitamin B12 deficiency in patients with PN using vitamin B12 (or ho-
lotranscobalamin) and MMA.70 Yetley et al. suggested using circulat-
ing vitamin B12 or holotranscobalamin and one functional marker, 
such as MMA or tHcy, to diagnose vitamin B12 deficiency.71 The cut- 
off values for vitamin B12 are debatable and some authors proposed 
using cut- off values up to 258 or 300 nmol/L (or 191– 222 pg/L) to 
capture all patients with probable deficiency.72 Detection of low vi-
tamin B12 in patients with PN could identify a subgroup of patients 
who may benefit from treatment.
A causal role for low B12 or elevated tHcy or MMA in neurop-
athy is uncertain, although the consistency in the evidence from 
observational and treatment studies in the present meta- analysis 
is suggestive of causality. Individuals who showed elevated tHcy 
after 6 years follow- up had lower nerve conduction velocity and 
abnormalities in monofilament compared to patients whose tHcy 
remained normal.41 Longitudinal studies are needed to show if low 
B- vitamins in subjects who are free of neuropathy may predict fu-
ture risk of the disease.
The associations between neuropathy and lowered vitamin B1 
and B6 were inconclusive possibly due to the low number of studies, 
although some studies that showed significant associations73,74 
could not be analyzed in the present study.
Limitations
The present study has some limitations. The search was limited to 
English language articles published in PubMed and Web of Science, 
which may have caused publication bias or overestimation of the 
associations. However, our study depending on biomarkers and in-
cluding PN associated with several diseases enabled us to synthe-
size evidence from a large number of studies, compared to previous 
systematic reviews.7,75 Overall the results were consistent in the di-
rection and the strength of the associations. The sensitivity and sub-
group analyses have shown small variations in the pooled estimates, 
while the loss of significance in the subgroup analyses could be due 
to the low number of studies. Finally, the association of low vitamin 
B12 status and the presence of neuropathy was confirmed by using 
three independent markers of vitamin B12 status, suggesting that 
the results were not due to chance.
Gaps in the literature and recommendations for 
future research
There are mechanistically plausible data on a possible role of folic acid 
as a neuroprotective vitamin. We did not intend to capture studies on 
folate concentrations because the widely applied fortification with 
folic acid can bias the associations. We encountered and analyzed 
data from 12 studies reporting on plasma folate and neuropathy (re-
sults are not based on systematic search). Most of the studies did 
not find lower concentrations of folate or higher prevalence of defi-
ciency in patients with PN compared to those without PN (Table S10). 
Plasma concentrations of tHcy could be elevated due to vitamin B12 
and/or folate deficiency. Identifying elevated tHcy levels implies ex-
ploring the cause and lowering tHcy by using the appropriate vita-
mins or their combinations, since tHcy itself could be neurotoxic.
Notably, the vitamin trials have shortcomings that limit extrap-
olation of the results to all patients with PN. The limitations include 
small sample size, short treatment duration (3– 24 weeks), and inclu-
sion of mainly diabetes neuropathy (with rather high heterogeneity). 
Moreover, it is not clear whether the treatment with the vitamins 
should be better tailored to patients with low vitamin concentra-
tions who are more likely to benefit. Future interventions should 
investigate vitamin statuses prior to administrating the vitamins.
CONCLUSIONS
We found that neuropathy was associated with lowered vitamin B12 
status as indicated by plasma vitamin B12, MMA, and tHcy. This associ-
ation was observed regardless of the primary disease that was believed 
to be the cause of neuropathy. The associations between neuropathy 
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and vitamin B1 and B6 deficiencies were inconclusive. Treatment of 
neuropathy is a challenge. The association between vitamin B1 and B12 
status and neuropathy symptoms or improvement after treatment sug-
gests that treating nutritional deficiencies (including lowering plasma 
tHcy) should be part of the healthcare management of neuropathy and 
all morbidities associated with high risk of neuropathy.
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